Department of Pathology and Laboratory Medicine.
Department of Pathology and Laboratory Medicine, Vancouver General Hospital.
Appl Immunohistochem Mol Morphol. 2023;31(5):304-310. doi: 10.1097/PAI.0000000000001122. Epub 2023 Apr 10.
Tumors of the central nervous system (CNS) in pediatric patients have undergone significant diagnostic refinement through the use of immunohistochemistry (IHC) and molecular techniques. The utility of these novel IHC antibodies has been demonstrated with the inactivation of the switch/sucrose nonfermenting (SWI/SNF) chromatin-remodeling complex in the diagnosis of atypical teratoid/rhabdoid tumors, predominantly through the loss of integrase interactor 1 (INI1; SMARCB1 ). Alternatively, these tumors may have inactivation of brahma-related gene 1 (BRG1; SMARCA4 ) in a subset of cases. The role of other SWI/SNF component proteins and their expression in pediatric brain tumors is not well established. Nestin, an intermediate filament, has been shown to be present in some pediatric CNS tumors, but of uncertain diagnostic and prognostic significance. We sought to explore the immunohistochemical expression profile for common SWI/SNF subunits and nestin in a pediatric CNS tumor cohort. Using a 118-sample tissue microarray, we performed IHC for INI1, BRG1, brahma (BRM), ARID1A, ARID1B, polybromo 1, and nestin. In 19 cases, INI1 was lost and BRG1 was lost in 2 cases. Interestingly, 6 cases originally diagnosed as primitive neuroectodermal tumors showed isolated loss of BRM. Other SWI/SNF proteins did not provide further diagnostic resolution. Nestin was positive in 76.2% of INI1/BRG1-deficient tumors, compared with 29.1% in INI1/BRG1-intact tumors yielding a sensitivity of 76.2%, specificity of 68.0%, and a P value of <0.001, but nestin positivity did not correlate specifically with poor outcomes. In conclusion, we confirm the utility of BRG1 IHC in the workup of pediatric CNS tumors, which may facilitate a difficult diagnosis when conventional markers are inconclusive, or as a first-line marker in cases where intraoperative smears are suggestive of atypical teratoid/rhabdoid tumor. Although nestin expression was associated with SWI/SNF inactivation, it did not yield statistically significant diagnostic or prognostic information in our study. Interestingly, we identified 6 tumors with isolated BRM IHC loss, the significance of which is uncertain but warrants further investigation.
儿童患者中枢神经系统(CNS)肿瘤通过免疫组织化学(IHC)和分子技术得到了显著的诊断细化。这些新型 IHC 抗体的效用已通过在诊断非典型畸胎瘤/横纹肌样瘤中失活开关/蔗糖非发酵(SWI/SNF)染色质重塑复合物得到证实,主要是通过整合子相互作用蛋白 1(INI1;SMARCB1)的丧失。或者,在一部分病例中,这些肿瘤可能会失活 brahma 相关基因 1(BRG1;SMARCA4)。其他 SWI/SNF 成分蛋白的作用及其在小儿脑肿瘤中的表达尚不清楚。巢蛋白是一种中间丝,已被证明存在于一些小儿 CNS 肿瘤中,但诊断和预后意义不确定。我们试图在小儿 CNS 肿瘤队列中探索常见的 SWI/SNF 亚基和巢蛋白的免疫组织化学表达谱。使用 118 个样本组织微阵列,我们对 INI1、BRG1、brahma(BRM)、ARID1A、ARID1B、多溴 1 和巢蛋白进行了 IHC。在 19 例中,INI1 缺失,BRG1 缺失 2 例。有趣的是,6 例最初诊断为原始神经外胚层肿瘤的病例表现出孤立的 BRM 缺失。其他 SWI/SNF 蛋白没有提供进一步的诊断分辨率。巢蛋白在 76.2%的 INI1/BRG1 缺陷肿瘤中呈阳性,而在 INI1/BRG1 完整肿瘤中呈阳性的比例为 29.1%,这使得敏感性为 76.2%,特异性为 68.0%,P 值<0.001,但巢蛋白阳性与不良预后没有特异性相关性。总之,我们证实了 BRG1 IHC 在小儿 CNS 肿瘤检查中的效用,当常规标志物不确定时,它可能有助于做出困难的诊断,或者在术中涂片提示非典型畸胎瘤/横纹肌样瘤时作为一线标志物。尽管巢蛋白表达与 SWI/SNF 失活相关,但在我们的研究中并未产生具有统计学意义的诊断或预后信息。有趣的是,我们发现 6 例肿瘤存在孤立的 BRM IHC 缺失,其意义尚不确定,但值得进一步研究。